Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405)-Reference-Cited by-同舟云学术

Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405)

Published:2022-06-20 Issue:9 Volume:27 Page:1404-1412
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Haratake Naoki,Shimokawa Mototsugu,Seto Takashi,Yoshioka Hiroshige,Yamamoto Nobuyuki,Nakagawa Kazuhiko,Mitsudomi Tetsuya

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-022-02193-x.pdf

Reference28 articles.

1. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128. https://doi.org/10.1016/s1470-2045(09)70364-x

2. Kris MG, Johnson BE, Berry LD et al (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311(19):1998–2006. https://doi.org/10.1001/jama.2014.3741

3. Recondo G, Facchinetti F, Olaussen KA et al (2018) Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol 15(11):694–708. https://doi.org/10.1038/s41571-018-0081-4

4. Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378(2):113–125. https://doi.org/10.1056/NEJMoa1713137

5. Ramalingam SS, Vansteenkiste J, Planchard D et al (2020) overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382(1):41–50. https://doi.org/10.1056/NEJMoa1913662

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the efficacy of artificial neural networks in predicting lung cancer recurrence: a retrospective study based on patient records;Translational Lung Cancer Research;2023-10

2. Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.3;Journal of Clinical Oncology;2023-04-10